Healthcare -
Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 0.84
-7.69 %
$ 3.08 M
Market Cap
-0.2
P/E
1. INTRINSIC VALUE
Balance Sheet
Shuttle Pharmaceuticals Holdings, Inc.
| Current Assets | 5.59 M |
| Cash & Short-Term Investments | 5.46 M |
| Receivables | 14.9 K |
| Other Current Assets | 114 K |
| Non-Current Assets | 359 K |
| Long-Term Investments | 0 |
| PP&E | 359 K |
| Other Non-Current Assets | 0 |
| Current Liabilities | 1.04 M |
| Accounts Payable | 283 K |
| Short-Term Debt | 648 K |
| Other Current Liabilities | 110 K |
| Non-Current Liabilities | 854 K |
| Long-Term Debt | 439 K |
| Other Non-Current Liabilities | 415 K |
EFFICIENCY
Earnings Waterfall
Shuttle Pharmaceuticals Holdings, Inc.
| Revenue | 0 |
| Cost Of Revenue | 6.81 K |
| Gross Profit | -6.81 K |
| Operating Expenses | 5.89 M |
| Operating Income | -5.89 M |
| Other Expenses | 700 K |
| Net Income | -6.59 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Shuttle Pharmaceuticals Holdings, Inc.
| Net Income | -6.59 M |
| Depreciation & Amortization | 6.81 K |
| Capital Expenditures | -19 K |
| Stock-Based Compensation | 182 K |
| Change in Working Capital | 221 K |
| Others | 669 K |
| Free Cash Flow | -5.6 M |
Wall Street Analysts Price Targets
Shuttle Pharmaceuticals Holdings, Inc.
SHPH has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
SHPH does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Shuttle Pharmaceuticals Holdings, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
2 years ago
Dec 29, 2022
|
Sell 2.61 K
USD
|
Senanayake Chris
Director
|
- 1626
|
1.605 USD |
|
1 year ago
Dec 13, 2023
|
Sell 1.35 K
USD
|
Brown Milton
Director
|
- 2921
|
0.4632 USD |
|
1 year ago
Dec 13, 2023
|
Sell 1.93 K
USD
|
Jacobs Bette
Director
|
- 4157
|
0.4632 USD |
|
2 years ago
Dec 29, 2022
|
Sell 1.6 K
USD
|
Richards Steven M
Director
|
- 995
|
1.605 USD |
|
2 years ago
Dec 29, 2022
|
Sell 1.6 K
USD
|
Adkins William
Director
|
- 995
|
1.605 USD |
|
2 years ago
Dec 29, 2022
|
Sell 1.6 K
USD
|
Brown Milton
Director
|
- 995
|
1.605 USD |
|
2 years ago
Dec 29, 2022
|
Sell 13.4 K
USD
|
Dritschilo Anatoly
CEO and Chairman
|
- 8372
|
1.605 USD |
|
2 years ago
Dec 29, 2022
|
Sell 2.27 K
USD
|
Rich Tyvin
Chief Medical Officer
|
- 1414
|
1.605 USD |
|
2 years ago
Dec 29, 2022
|
Sell 526
USD
|
Jung Mira
Chief Scientific Officer
|
- 328
|
1.605 USD |
|
2 years ago
Dec 29, 2022
|
Sell 7.01 K
USD
|
Jacobs Bette
Director
|
- 4366
|
1.605 USD |
|
2 years ago
Dec 29, 2022
|
Sell 6.13 K
USD
|
Dritschilo Peter
President and COO
|
- 3820
|
1.605 USD |
|
2 years ago
Dec 29, 2022
|
Sell 3.6 K
USD
|
Vander Hoek Michael
Chief Financial Officer
|
- 2243
|
1.605 USD |
7. News
Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
GAITHERSBURG, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that CEO, Anatoly Dritschilo, M.D., will participate in a webcasted fireside chat at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monday, January 13, 2025.
globenewswire.com
- 1 week ago
Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient
GAITHERSBURG, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today first patient enrollment and dosing at the UVA Cancer Center in its Phase 2 Clinical Trial of Ropidoxuridine for the treatment of patients with glioblastoma. UVA is one of six cancer centers conducting the clinical trials. Shuttle Pharma previously announced the dosing of patients at Miami Cancer Institute, part of Baptist Health South Florida.
globenewswire.com
- 1 month ago
Shuttle Pharma Provides Third Quarter 2024 Corporate Update
GAITHERSBURG, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the third quarter ended September 30, 2024.
globenewswire.com
- 2 months ago
Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
GAITHERSBURG, Md., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the pricing of its "reasonable best efforts" public offering with a health-care focused institutional investor for the purchase and sale of up to 2,950,820 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 2,950,820 shares of common stock at a combined offering price of $1.525 per share and accompanying warrant, priced at-the-market under Nasdaq rules (the “Offering”). The Company expects to receive aggregate gross proceeds of approximately $4.5 million, before deducting placement agent fees and other offering expenses, and assuming no exercise of the warrants. The warrants will have an exercise price of $1.40 per share, will be exercisable immediately and will expire five years from the issuance date.
globenewswire.com
- 2 months ago
Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma
GAITHERSBURG, Md., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today it has finalized agreements with all six of the planned site enrollment locations to administer the Phase 2 clinical trial of Ropidoxuridine for the treatment of patients with glioblastoma following the entry into agreements with Georgetown University Medical Center and UNC Medical Center. The Company previously entered agreements with UVA Cancer Center, John Theurer Cancer Center at Hackensack University Medical Center, Allegheny Health Network (AHN) Cancer Institute, and Miami Cancer Institute, part of Baptist Health South Florida. Patients are currently undergoing screening for enrollment in the trial.
globenewswire.com
- 2 months ago
Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma
GAITHERSBURG, Md., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today it has entered into agreements with two additional site locations to administer the Phase 2 clinical trial of Ropidoxuridine for the treatment of patients with glioblastoma. Four of the planned six trial sites are now prepared to enroll patients in the clinical trial, including the UVA Cancer Center, John Theurer Cancer Center at Hackensack University Medical Center, Allegheny Health Network (AHN) Cancer Institute, and Miami Cancer Institute, part of Baptist Health South Florida.
globenewswire.com
- 4 months ago
Shuttle Pharma Provides Second Quarter 2024 Corporate Update
GAITHERSBURG, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the second quarter ended June 30, 2024.
globenewswire.com
- 4 months ago
Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)
GAITHERSBURG, Md., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today reports that it received formal notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) that it is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) as a result of the Company's failure to timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2024 (the “Q2 Quarterly Report”).
globenewswire.com
- 4 months ago
Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
GAITHERSBURG, Md., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today it has entered into agreements with two of the six site locations to administer the Phase 2 clinical trial of Ropidoxuridine for the treatment of patients with glioblastoma. Site initiation visits have been completed for two sites. The trial is now open to enroll patients in the clinical trial.
globenewswire.com
- 5 months ago
Shuttle Pharma's Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE
GAITHERSBURG, Md., July 19, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the publication of a manuscript reporting on the ability of one of the Company's HDAC inhibitor pre-clinical assets, SP-1-303, which exhibits ataxia-telangiectasia mutated protein (ATM) activation and modulation of estrogen receptor expression resulting in substantial growth inhibition of estrogen receptor positive breast cancer cells (ER + BC).
globenewswire.com
- 6 months ago
Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer
Current CFO, Michael Vander Hoek, transitions to full-time Vice President, Regulatory Current CFO, Michael Vander Hoek, transitions to full-time Vice President, Regulatory
globenewswire.com
- 7 months ago
Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
GAITHERSBURG, Md., May 22, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced that Dr. Anatoly Dritschilo, Chief Executive Officer, will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2024 Investor Conference, taking place virtually on Thursday, May 30, 2024.
globenewswire.com
- 7 months ago
8. Profile
Summary
Shuttle Pharmaceuticals Holdings, Inc. SHPH
COUNTRY
US
INDUSTRY
Drug Manufacturers - Specialty & Generic
MARKET CAP
$ 3.08 M
Dividend Yield
0.00%
Description
Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.
Contact
One Research Court, Rockville, MD, 20850
https://www.shuttlepharma.com
IPO
Date
Aug. 31, 2022
Employees
8
Officers
Dr. Milton Brown CSC, M.D., Ph.D.
Co-Founder & Director
Mr. Gene Jung Esq.
General Counsel
Dr. Mira Jung Ph.D.
Co-Founder & Chief Scientific Officer for Biology
Mr. Peter Dale Dritschilo M.B.A., M.D.
President & Chief Operating Officer
Dr. Tyvin A. Rich M.D.
Chief Clinical Officer & Chief Medical Officer
Dr. Anatoly Dritschilo M.D.
Co-Founder, Chief Executive Officer & Chairman of the Board